Yulei Wang

VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment.

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers.

Modified Pulsatilla decoction ameliorates ulcerative colitis by affecting gut microbiota and metabolite profiles

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma.

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation

Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.

Molecular subtypes of hepatocellular carcinoma linked to liver cell lineages and clinical outcomes of combination immunotherapy.

Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation.

Supplementary Figure S3 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Supplementary Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Supplementary Figure S1 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Data from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Supplementary Figure S2 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Supplementary Figure S4 from NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC

G protein–coupled estrogen receptor 1 ameliorates nonalcoholic steatohepatitis through targeting AMPK-dependent signaling

NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

Therapeutic and immune-regulation effects of Scutellaria baicalensis Georgi polysaccharide on pseudorabies in piglets

Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors.

Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC).

In situ tumour arrays reveal early environmental control of cancer immunity

In situ tumour arrays reveal early environmental control of cancer immunity.

Protective effects of genistein on the production performance and lipid metabolism disorders in laying hens with fatty liver hemorrhagic syndrome by activation of the GPER–AMPK signaling pathways

Genistein alleviates chronic heat stress-induced lipid metabolism disorder and mitochondrial energetic dysfunction by activating the GPR30-AMPK-PGC-1α signaling pathways in the livers of broiler chickens

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma